We have previously reported that RCC2 is an independent prognostic biomarker in primary CRC (in Norwegian series 1).19 In the present study, this was validated in an independent series from the same hospital, but only in patients who did not receive adjuvant chemotherapy. This evidence concerns the gene RCC2 and colorectal carcinoma.